Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
Results Reported From Three NCI-Sponsored Clinical Trials
SOUTH SAN FRANCISCO, CA June 28, 2007 - Cytokinetics,
Incorporated (Nasdaq: CYTK) announced results from the analyses of
three Phase II clinical trials of ispinesib
monotherapy, one in patients with hepatocellular cancer, ...
Cytokinetics Announces Non-clinical Data to be Presented at the
2007 AACR Annual Meeting
...M, PT, Poster Section 27, Poster Board 14.)
has been the subject of a broad Phase II clinical
...h the continued development of the KSP inhibitors, ispinesib
SB-743921, subject to GSK's option to resume r... have shown an
acceptable tolerability profile for ispinesib
in combination with
standard chemotherapeutics. Cy...